Back to search

Article

CHAMPIONS: A phase 1/2 clinical trial with dose escalation of SB-913 ZFN-mediated in vivo human genome editing for treatment of MPS II (Hunter syndrome)

2019-02-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b857bedc-118a-5a39-8b6b-918e2eec231e
DOI
10.1016/j.ymgme.2018.12.263
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
CHAMPIONS: A phase 1/2 clinical trial with dose escalation of SB-913 ZFN-mediated in vivo human genome editing for treatment of MPS II (Hunter syndrome)DOI 10.1016/j.ymgme.2018.12.263
First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I/II and hemophilia BSemantic proximity
A New Class of Medicines through DNA EditingSemantic proximity
Human genetic diversity alters off-target outcomes of therapeutic gene editingSemantic proximity
ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler SyndromeSemantic proximity
An LNP-CRISPR gene editing drug demonstrates efficacy and safety in patients with hereditary angioedema following in vivo administrationSemantic proximity
A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type ISemantic proximity
Genome Editing for MucopolysaccharidosesSemantic proximity
Sangamo's landmark genome editing trial gets mixed receptionSemantic proximity
Engineered mtZFNs for Manipulation of Human Mitochondrial DNA Heteroplasmy.Semantic proximity
Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing.Semantic proximity
CRISPR-Based Therapy for Hereditary AngioedemaSemantic proximity
IN VIVO CRISPR/CAS9 EDITING OF KLKB1 IN PATIENTS WITH HEREDITARY ANGIOEDEMA: A FIRST-IN-HUMAN STUDYSemantic proximity
Select a neighboring publication to make it the new centre.